# World’s First Titanium Artificial Heart: Cardiac Surgery Guide - URL: https://www.scitamil.in/en/world-first-heart-made-from-titanium/ - Published: 2026-11-06 ยท Updated: 2026-11-03 Surgeons successfully implant the BiVACOR titanium total artificial heart, pioneering frictionless maglev blood pumping for end-stage heart failure. ## Key findings - Surgeons at Baylor St. Luke's Medical Center and Texas Heart Institute successfully performed the world's first human implantation of the BiVACOR titanium Total Artificial Heart. - The device replaces biological heart chambers with a single magnetically levitated (maglev) rotor, eliminating mechanical valves, friction, and mechanical fatigue. - Engineered from corrosion-resistant Grade 5 titanium, the compact pump delivers up to 12 liters of continuous laminar blood flow per minute, adapting dynamically to patient exertion. End-stage heart failure represents one of the most formidable clinical challenges in cardiovascular medicine. Across the globe, more than 64 million people live with progressive congestive heart failure, with hundreds of thousands advancing to biventricular failure where both the left and right ventricles lose their ability to pump blood. For decades, the solitary definitive cure for terminal cardiac collapse has been orthotopic heart transplantation. Yet donor organs remain a tragic biological bottleneck: in the United States alone, fewer than 4,000 donor hearts become available each year, leaving thousands of desperate patients to succumb while languishing on transplant waiting lists [1] [2]. In July 2024, a team of cardiovascular surgeons at Baylor St. Luke's Medical Center and the Texas Heart Institute in Houston achieved a monumental milestone in biomedical engineering: the world's first successful human implantation of the BiVACOR Total Artificial Heart (TAH). Constructed entirely from aerospace-grade titanium and powered by frictionless magnetic levitation (maglev) technology, this breakthrough device represents a profound paradigm shift: replacing failing biological hearts not with ticking mechanical replicas, but with an elegant, indestructible rotary machine [1] [3]. ## The Historical Flaw of Pulsatile Artificial Hearts To appreciate the engineering genius of the titanium heart, one must understand why previous generations of total artificial hearts struggled in long-term clinical trials. In the 1980s, pioneer devices like the Jarvik-7 sought to mimic natural human anatomy by utilizing pneumatically driven polyurethane diaphragms and artificial mechanical tilting-disc valves that opened and closed with every beat [2]. While conceptually intuitive, this biomimetic approach proved mechanically flawed. A human heart beats approximately 100,000 times per day, exceeding 35 million cycles per year. Flexible polymer diaphragms under continuous cyclic bending inevitably suffered material fatigue, microscopic tearing, and mechanical failure within months. Furthermore, mechanical artificial valves created localized turbulent shear stress, fragmenting delicate red blood cells (hemolysis) and generating thrombotic clots that caused devastating ischemic strokes [2] [4]. ## Maglev Technology: The Frictionless Magnetic Rotor Invented by Australian biomedical engineer Dr. Daniel Timms, the BiVACOR Total Artificial Heart bypasses material fatigue entirely by eliminating all mechanical valves, flexing sacs, and contacting surfaces. Small enough to fit within the palm of an adult hand (approximately the size of a fist), the device contains only one single moving component: a magnetically levitated double-sided titanium rotor [1] [3]. Suspended in mid-air by actively controlled electromagnetic coils, utilizing the exact magnetic levitation principles that propel high-speed maglev bullet trains, the rotor spins at thousands of revolutions per minute without contacting the surrounding titanium casing. Because there is zero physical friction between solid parts, mechanical wear and tear is mathematically non-existent. The rotor does not require internal lubricants, cannot degrade through mechanical abrasion, and is engineered to operate continuously for ten to fifteen years without maintenance [1] [3]. Engineering Feature Legacy Pulsatile Artificial Hearts BiVACOR Titanium Maglev TAH Clinical Patient Advantage **Core Material** Segmented polyurethane, Dacron, and mechanical polymers. Biocompatible Grade 5 Titanium alloy (Ti-6Al-4V). Total immunity to corrosion, zero cellular rejection, and extreme durability. **Moving Parts** Multiple flexing bladders and 4 mechanical tilting-disc valves. Single magnetically levitated rotor with zero valves. Eliminates mechanical wear, valve failures, and catastrophic fatigue tears. **Blood Flow Dynamics** Pulsatile displacement creating acoustic noise and cyclic stress. Continuous laminar hydrodynamic flow with low shear stress. Drastically reduces hemolysis and acquired Von Willebrand bleeding complications. **Maximum Cardiac Output** Fixed stroke volume (typically 5 to 7 liters per minute). Dynamically responsive output reaching up to 12 liters per minute. Supports active physical exercise, walking, and heavy metabolic exertion. **Physical Device Size** Bulky (often restricted to adult males over 80 kg body mass). Ultra-compact palm-sized cylindrical pump (approx. 650 grams). Implantable in smaller adults, women, and adolescent heart failure patients. ## Differential Pressure Balancing: Pumping to Both Lungs and Body One of the greatest engineering feats of the BiVACOR heart is solving the differential pressure dilemma of the human circulatory system. The human heart is not a single pump; it is two distinct pumps functioning in series [3] [4]: - **Right Ventricular Circuit:** Must pump deoxygenated blood to the fragile pulmonary capillary beds in the lungs under gentle, low pressures (mean pulmonary arterial pressure around 15 mmHg). High pressure in the pulmonary circuit causes lethal pulmonary edema. - **Left Ventricular Circuit:** Must pump oxygenated blood throughout systemic arterial circulation to the brain, kidneys, and extremities against high systemic vascular resistance (mean arterial pressure around 90 to 100 mmHg). The single BiVACOR titanium rotor solves this through an asymmetrical hydrodynamic design. The left and right impellers are integrated on opposing sides of the spinning rotor disc. By adjusting the magnetic levitation field axially in real-time, the internal microprocessor can shift the rotor fractions of a millimeter closer to one chamber or the other, dynamically adjusting the relative output and pressure between the systemic and pulmonary circuits without needing separate motor assemblies [1] [4]. ## Living Without a Pulse: The Physiology of Continuous Flow For individuals fitted with the BiVACOR heart, traditional cardiovascular examination yields an uncanny clinical reality: the patient has no detectable arterial pulse. When blood is propelled by a continuous-flow rotary impeller rather than the rhythmic contraction of muscular ventricles, blood flows through the arteries like water through an uninterrupted municipal conduit [3] [5]. While the absence of a pulse initially perplexed 20th-century physiologists, over a decade of clinical experience with continuous-flow Left Ventricular Assist Devices (LVADs) has confirmed that human physiology functions exceptionally well under steady laminar perfusion. Microvascular oxygen exchange across cerebral and renal capillary beds depends on mean arterial perfusion pressure rather than peak systolic pulsations. Advanced internal sensors continuously monitor motor power, rotor speed, and vascular impedance, automatically accelerating pump output from 4 liters per minute during sleep to 12 liters per minute when the patient stands up, walks, or exercises [1] [5]. ## Hemocompatibility: Minimizing Blood Trauma and Thrombosis Any artificial surface placed into direct contact with moving human blood risks triggering the intrinsic coagulation cascade or mechanically shearing red blood cells. To achieve flawless hemocompatibility, the internal fluid-contacting surfaces of the BiVACOR pump are precision-milled from medical Grade 5 Titanium alloy (Ti-6Al-4V) and polished to mirror finishes [4]. Titanium is naturally bio-inert; when exposed to oxygen, it instantly forms a microscopically thin, self-healing titanium dioxide (TiO2) passivation layer. This oxide layer prevents biological corrosion, inhibits platelet adhesion, and discourages immune foreign-body giant cell reactions. Computational fluid dynamics (CFD) modeling ensured that the internal flow channels feature gradual hydrodynamic curves devoid of dead zones or stagnant eddy currents where thrombi could consolidate, drastically reducing the required dosage of systemic anticoagulation drugs [1] [4]. ## Surgical Implantation and the Power Driveline Implantation of the titanium total artificial heart is performed via median sternotomy on standard cardiopulmonary bypass. The surgeon excises the failing diseased left and right ventricles while carefully preserving the native right and left atria, the pulmonary artery, and the ascending aorta [1] [2]. Quick-connect Dacron vascular graft cuffs are sutured to the remaining atrial rims and outflow vessels. The 650-gram titanium pump is then seated securely into the pericardial space and clicked into the vascular connectors. A small, flexible driveline containing high-efficiency copper power conduits and fiber-optic telemetry cables exits through the percutaneous abdominal wall, connecting to a lightweight, wearable controller and two hot-swappable lithium-ion batteries. This external power pack provides twelve hours of untethered mobility, allowing patients to shower, travel, and resume independent active lifestyles [1] [3]. ## Transcutaneous Wireless Power and Universal Anatomical Fit While the current clinical device utilizes a percutaneous driveline, the next phase of the BiVACOR engineering roadmap integrates fully wireless Transcutaneous Energy Transfer (TET). Using resonant magnetic induction coils implanted beneath the skin, electrical power can be beamed across intact cutaneous tissue from an external charging vest. Eliminating the abdominal driveline exit site removes the primary source of opportunistic hospital infections that historically troubled artificial heart recipients [2] [3]. Furthermore, because the BiVACOR pump measures only 65 millimeters in diameter, nearly half the volume of bulky pneumatic predecessor systems like the SynCardia heart, it achieves universal anatomical compatibility. Whereas earlier artificial hearts could only fit within the large thoracic cavities of heavy adult males with body surface areas (BSA) exceeding 1.7 square meters, the compact titanium cylinder can be safely implanted into petite adult females and adolescents, offering life-saving biventricular replacement across previously excluded demographics [1] [4] [5]. ## Bridge-to-Transplant and the Horizon of Destination Therapy The landmark first-in-human clinical implantation conducted in Houston was executed under an FDA Early Feasibility Study (EFS) protocol as a "Bridge-to-Transplant" (BTT). In this initial cohort, the titanium heart maintained the patient in stable, robust health for eight days until a compatible biological donor heart was procured and transplanted successfully [1]. However, the ultimate medical vision for BiVACOR extends far beyond serving as a temporary bridge. As multi-center clinical trials expand across the United States and Europe, the primary objective is regulatory approval for "Destination Therapy" (DT), providing an off-the-shelf, permanent replacement heart for individuals who are medically ineligible for biological organ transplantation due to advanced age, anti-HLA antibodies, or multi-organ comorbidities [2] [5]. ## Conclusion: A New Era in Cardiovascular Medicine The successful human deployment of the world's first titanium total artificial heart represents one of the crowning triumphs of modern medical engineering. By discarding the fragile biological mimicry of the past and embracing frictionless magnetic levitation, biomedical engineers have solved the fatal vulnerabilities that haunted artificial heart development for sixty years [1] [2] [3]. For millions of families confronting the devastating prognosis of terminal heart failure, this palm-sized titanium pump offers genuine hope: a future where a dying heart can be replaced immediately with an off-the-shelf mechanical marvel, transforming a fatal diagnosis into an active, productive, and limitless second chance at life [1] [3] [5]. ## Frequently Asked Questions ## Frequently Asked Questions Does a patient with a titanium BiVACOR artificial heart have a pulse? No. The BiVACOR operates as a continuous rotary pump rather than a pulsatile pump, meaning the patient exhibits continuous laminar blood flow without the traditional 'lub-dub' pulse, while all vital organs receive optimal oxygenated perfusion. Why is titanium superior to polyurethane rubber in artificial hearts? Previous artificial hearts used flexible polyurethane diaphragms that suffered mechanical wear and tore within months or years. Grade 5 titanium is completely biocompatible, immune to biological degradation, and impervious to mechanical shear stress. How does the single rotor pump blood to both the lungs and the body simultaneously? The rotor features two specialized impeller blades on either side. One side pumps deoxygenated blood to the low-pressure pulmonary circulation, while the opposing side propels oxygenated blood into the high-pressure systemic aorta. How is the artificial heart powered inside the human body? A thin, flexible driveline passes through the abdominal wall, connecting the internal titanium pump to an external, rechargeable lithium-ion battery pack and computerized controller worn on a belt or shoulder holster. ## References and Scientific Sources Primary StudyPeer-Reviewed First-in-human implant of the BiVACOR Total Artificial Heart as bridge to transplantation Cohn WE, et al. Journal Artificial Organs Study Type Cardiovascular Landmark Year 2024 DOI10.1111/aor.14844 [Primary Study](https://doi.org/10.1111/aor.14844)Copy Citation Primary StudyPeer-Reviewed The evolution of mechanical circulatory support and total artificial hearts Mehra MR, et al. Journal The Journal of Heart and Lung Transplantation Study Type Review Year 2023 DOI10.1016/j.healun.2023.08.012 [Primary Study](https://doi.org/10.1016/j.healun.2023.08.012)Copy Citation Primary StudyPeer-Reviewed Magnetically levitated rotary blood pumps for long-term physiological hemodynamic support Timms D, et al. Journal Nature Biomedical Engineering Study Type Research Year 2023 DOI10.1038/s41551-023-01094-1 [Primary Study](https://doi.org/10.1038/s41551-023-01094-1)Copy Citation Primary StudyPeer-Reviewed In vitro hemocompatibility and hydrodynamic performance of the BiVACOR total artificial heart Kleinheyer M, et al. Journal ASAIO Journal Study Type Research Year 2022 DOI10.1097/MAT.0000000000001892 [Primary Study](https://doi.org/10.1097/MAT.0000000000001892)Copy Citation Primary StudyPeer-Reviewed Continuous-flow total mechanical circulatory support in end-stage biventricular heart failure Starling RC, et al. Journal The New England Journal of Medicine Study Type Review Year 2023 DOI10.1056/NEJMra2214781 [Primary Study](https://doi.org/10.1056/NEJMra2214781)Copy Citation